These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37755427)

  • 21. The Chronicity of HIV Infection Should Drive the Research Strategy of NeuroHIV Treatment Studies: A Critical Review.
    Gates TM; Cysique LA
    CNS Drugs; 2016 Jan; 30(1):53-69. PubMed ID: 26749584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuroactive antiretroviral drugs do not influence neurocognitive performance in less advanced HIV-infected patients responding to highly active antiretroviral therapy.
    Giancola ML; Lorenzini P; Balestra P; Larussa D; Baldini F; Corpolongo A; Narciso P; Bellagamba R; Tozzi V; Antinori A
    J Acquir Immune Defic Syndr; 2006 Mar; 41(3):332-7. PubMed ID: 16540934
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interrogating the impact of combination antiretroviral therapies on HIV-associated neurocognitive disorders.
    Sharma I
    HIV Med; 2021 Oct; 22(9):783-790. PubMed ID: 34291558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of age and time of disease with HIV-associated neurocognitive disorders: a Japanese nationwide multicenter study.
    Kinai E; Komatsu K; Sakamoto M; Taniguchi T; Nakao A; Igari H; Takada K; Watanabe A; Takahashi-Nakazato A; Takano M; Kikuchi Y; Oka S;
    J Neurovirol; 2017 Dec; 23(6):864-874. PubMed ID: 28971376
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The far-reaching HAND of cART: cART effects on astrocytes.
    Gonzalez H; Podany A; Al-Harthi L; Wallace J
    J Neuroimmune Pharmacol; 2021 Mar; 16(1):144-158. PubMed ID: 32147775
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Variable benefit in neuropsychological function in HIV-infected HAART-treated patients.
    Cysique LA; Maruff P; Brew BJ
    Neurology; 2006 May; 66(9):1447-50. PubMed ID: 16682686
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiretroviral treatment initiation does not differentially alter neurocognitive functioning over time in youth with behaviorally acquired HIV.
    Nichols SL; Bethel J; Kapogiannis BG; Li T; Woods SP; Patton ED; Ren W; Thornton SE; Major-Wilson HO; Puga AM; Sleasman JW; Rudy BJ; Wilson CM; Garvie PA;
    J Neurovirol; 2016 Apr; 22(2):218-30. PubMed ID: 26463526
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV-associated neurocognitive disorders and the impact of combination antiretroviral therapies.
    Ances BM; Clifford DB
    Curr Neurol Neurosci Rep; 2008 Nov; 8(6):455-61. PubMed ID: 18957181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. AIDS dementia complex: response to highly active antiretroviral therapy.
    Maddocks S; Iredell J
    AIDS; 1999 Dec; 13(17):2490-1. PubMed ID: 10597800
    [No Abstract]   [Full Text] [Related]  

  • 30. Neurocognitive Impairment in a Chronically Well-Suppressed HIV-Infected Population: The Dutch TREVI Cohort Study.
    van den Dries LWJ; Wagener MN; Jiskoot LC; Visser M; Robertson KR; Adriani KS; van Gorp ECM
    AIDS Patient Care STDS; 2017 Aug; 31(8):329-334. PubMed ID: 28753395
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacologic approaches to HIV-associated neurocognitive disorders.
    Avedissian SN; Dyavar SR; Fox HS; Fletcher CV
    Curr Opin Pharmacol; 2020 Oct; 54():102-108. PubMed ID: 33049585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV encephalitis in a patient on antiretroviral therapy: a case report.
    Hlebowicz M; Parczewski M; Jakubowski P
    Int J STD AIDS; 2019 May; 30(6):617-619. PubMed ID: 30722753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neurological disease: the effects of HIV and antiretroviral therapy and the implications for early antiretroviral therapy initiation.
    Wright EJ
    Curr Opin HIV AIDS; 2009 Sep; 4(5):447-52. PubMed ID: 20048710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CNS Neurotoxicity of Antiretrovirals.
    Lanman T; Letendre S; Ma Q; Bang A; Ellis R
    J Neuroimmune Pharmacol; 2021 Mar; 16(1):130-143. PubMed ID: 31823251
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of HIV in the CNS: effects of antiretroviral therapy and the promise of non-antiretroviral therapeutics.
    Peluso MJ; Spudich S
    Curr HIV/AIDS Rep; 2014 Sep; 11(3):353-62. PubMed ID: 25063356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anemia and Red Blood Cell Indices Predict HIV-Associated Neurocognitive Impairment in the Highly Active Antiretroviral Therapy Era.
    Kallianpur AR; Wang Q; Jia P; Hulgan T; Zhao Z; Letendre SL; Ellis RJ; Heaton RK; Franklin DR; Barnholtz-Sloan J; Collier AC; Marra CM; Clifford DB; Gelman BB; McArthur JC; Morgello S; Simpson DM; McCutchan JA; Grant I;
    J Infect Dis; 2016 Apr; 213(7):1065-73. PubMed ID: 26690344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV-associated neurological disorders: a guide to pharmacotherapy.
    Tan IL; McArthur JC
    CNS Drugs; 2012 Feb; 26(2):123-34. PubMed ID: 22201342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurocognitive impairment among HIV-positive individuals in Botswana: a pilot study.
    Lawler K; Mosepele M; Ratcliffe S; Seloilwe E; Steele K; Nthobatsang R; Steenhoff A
    J Int AIDS Soc; 2010 Apr; 13():15. PubMed ID: 20406460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Motor function and human immunodeficiency virus-associated cognitive impairment in a highly active antiretroviral therapy-era cohort.
    Robinson-Papp J; Byrd D; Mindt MR; Oden NL; Simpson DM; Morgello S;
    Arch Neurol; 2008 Aug; 65(8):1096-101. PubMed ID: 18695060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1.
    Taiwo B; Hicks C; Eron J
    J Antimicrob Chemother; 2010 Jun; 65(6):1100-7. PubMed ID: 20348088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.